Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) Shares Outstanding (2016 - 2025)

Marimed has reported Shares Outstanding over the past 15 years, most recently at $396.9 million for Q4 2025.

  • Quarterly Shares Outstanding rose 4.05% to $396.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $396.9 million through Dec 2025, up 4.05% year-over-year, with the annual reading at $396.9 million for FY2025, 4.05% up from the prior year.
  • Shares Outstanding was $396.9 million for Q4 2025 at Marimed, up from $394.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $396.9 million in Q4 2025 and troughed at $5025.0 in Q1 2023.
  • The 5-year median for Shares Outstanding is $375.1 million (2023), against an average of $274.4 million.
  • Year-over-year, Shares Outstanding skyrocketed 1064009.61% in 2021 and then crashed 99.98% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $331.5 million in 2021, then tumbled by 99.98% to $70000.0 in 2022, then skyrocketed by 535794.79% to $375.1 million in 2023, then grew by 1.69% to $381.5 million in 2024, then grew by 4.05% to $396.9 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Shares Outstanding are $396.9 million (Q4 2025), $394.5 million (Q3 2025), and $392.0 million (Q2 2025).